• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice the COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice)
【2h】

Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice the COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice)

机译：在日常实践中对依维莫司和紫杉醇洗脱支架进行冠脉血运重建的随机对照试验的最后5年随访随访COMPARE试验（在日常实践中对依维莫司和紫杉醇洗脱支架和紫杉醇支架进行冠脉血运重建的试验）

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

textabstractObjectives This study sought to report the 5-year outcomes of everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES) in an all-comers population undergoing percutaneous coronary intervention (PCI). Background The medium-term 1 and 2-year results of the prospective randomized COMPARE trial (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) showed superior clinical outcomes with EES compared with PES in an all-comers PCI population. Whether this benefit is sustained over longer-term follow-up is unknown. Furthermore, systematic long-term follow-up data on these metallic drug eluting stents with durable polymers are scarce. Methods We randomly assigned 1,800 patients undergoing PCI to EES or PES. The pre-specified composite primary endpoint was death, myocardial infarction (MI), or target vessel revascularization (TVR). Results Follow-up at 5 years was completed in 1,791 (99.5%) patients. Treatment with EES compared with PES led to a relative risk reduction of the primary endpoint by 27% (18.4% vs. 25.1%, p = 0.0005), driven by lower rates of MI (7.0% vs. 11.5%, p = 0.001) and TVR (7.4% vs. 11.4%, p = 0.003), but not with mortality (9.0% vs. 10.3%, relative risk 0.88, p = 0.36). Moreover, patients treated with EES compared with PES had lower rates of definite/probable stent thrombosis at 5 years (3.1% vs. 5.9%, p = 0.005). The hazard curves for TVR, MI, and stent thrombosis diverge over the first 3 years and, subsequently, progress in parallel. Conclusions The early- and medium-term superiority of EES over PES measured both by safety and efficacy endpoints is sustained at 5 years in this all-comer population. (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice [COMPARE]; NCT01016041).
机译：textabstractObjectives这项研究试图报告在接受经皮冠状动脉介入治疗（PCI）的所有人群中，依维莫司洗脱支架（EES）和紫杉醇洗脱支架（PES）的5年结果。背景前瞻性随机COMPARE试验的中期（一年和两年）结果（每日实践中使用依维莫司洗脱支架和紫杉醇洗脱支架进行冠状动脉血运重建试验）显示，在所有患者中，EES均优于PES。角PCI人口。这种益处是否在长期随访中得以维持尚不清楚。此外，缺乏关于这些具有耐用聚合物的金属药物洗脱支架的系统的长期随访数据。方法我们将1800例接受PCI的患者随机分配到EES或PES。预先指定的复合主要终点是死亡，心肌梗塞（MI）或目标血管血运重建（TVR）。结果1,791（99.5％）名患者完成了5年的随访。与MIS相比，EES治疗使主要终点的相对风险降低了27％（18.4％对25.1％，p = 0.0005），这是由于MI发生率较低（7.0％对11.5％，p = 0.001）所致和TVR（7.4％对11.4％，p = 0.003），但死亡率却不对（9.0％对10.3％，相对风险0.88，p = 0.36）。此外，与PES相比，接受EES治疗的患者在5年内明确/可能的支架血栓形成率较低（3.1％对5.9％，p = 0.005）。在最初的三年中，TVR，MI和支架血栓形成的危险曲线不同，并且随后并行发展。结论通过安全性和有效性终点评估，EES在PES的早期和中期优势在5岁以下人群中得以维持。 （在日常实践中，使用依维莫司洗脱支架和紫杉醇洗脱支架进行冠脉血运重建的试验[COMPARE]； NCT01016041）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号